FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2525156743> ?p ?o ?g. }

• W2525156743 abstract "Abstract In the last years, the use of rituximab administered with the same schedule used for treatment of B-cell non Hodgkin’s lymphomas (375 mg/sqm weekly for 4 weeks) has been extended to the management of the autoimmune cytopenias, such as the warm-type autoimmune haemolytic anaemia (AIHA). The rational for this therapeutic approach is that B-cell depletion induced by rituximab interferes with the production of autoantibodies against red cells but the mechanism of action has not been completely elucidated and the optimal schedule has not been established yet. In the setting of autoimmune cytopenias, biological and clinical evidences suggest the feasibility of lower doses of rituximab. Low dose schedule of rituximab (100 mg weekly for 4 weeks) was tested in a 78-year old man with a long lasting and symptomatic IgG warm-type idiopathic AIHA who was ineligible to splenectomy and resistant to steroids, immunosuppressive agents and high-dose intravenous immunoglobulins. The absence of an underlying lymphoproliferative disease, the age and the purpose to reduce the immunosuppressive effects were the reasons of our choice. Rituximab were administered intravenously at a dose of 100 mg weekly for 4 consecutive weeks in September 2007. Neither extra-hematological (infusion-related reactions, nausea or infections) nor hematological (leucopenia, neutropenia, and thrombocytopenia) toxicities were observed. The haematological and laboratory data before rituximab were the following: haemoglobin (Hb) 8,9 g/dl (supported with 4 packed red-cell transfusions in the previous 2 months), lactate dehydrogenase (LDH) 250 U/L, indirect bilirubin 3,8 mg/dl, haptoglobin 0 mg/dl, reticulocyte count 84%. Complete response (CR = Hb &gt; 12 g/dl, transfusion independence and absence of clinical and laboratory signs of haemolysis for at least 4 weeks after rituximab treatment, irrespective of direct antiglobulin test positivity) was rapidly achieved at the 6th week and it was maintained until the 29th week. A deep B-cell depletion was documented after 12th week and confirmed at 24th week (CD20 positive cells were uncountable). As frequently observed in the majority of the cases reported in the literature on standard dose rituximab, after 6 months of CR, AIHA relapsed with clinical features and haematological and laboratory signs of haemolysis (Hb 8,3 gr/dl, LDH 170 U/L, indirect bilirubin 2,27 mg/dl, haptoglobin 24 mg/dl and reticulocyte count 35%). A second course of low dose schedule rituximab (100 mg weekly for 4 weeks) was administered and a second CR was documented after 15 weeks. At the last follow up, 23 weeks from the second course of low-dose rituximab (51st week from the first course), the patient is in continuous second CR (Hb 13.9 gr/dl, LDH 150 U/L, indirect bilirubin 0,5 mg/dl, haptoglobin 100 mg/dl and reticulocyte count 1%). As the first course, nor extra-haematological neither haematological toxicities were observed. In particular, although a marked B-cell depletion was continuously documented from the 12th week until the last follow up (51st week), none infective episode occurred. Considering its good safety profile, maintenance therapy with 100 mg of rituximab every 2 months has been planned in attempt to prevent a new relapse. Our report suggests that low dose rituximab could be able to induce a complete and long lasting CR in refractory/relapsed warm AIHA at least as the standard dose. Moreover, low dose rituximab may be effective also after a relapse, but, interestingly, with a slower time of response than the one observed during the first course (6th vs 15th week). Considering the efficacy and the good safety profile, low dose schedule rituximab could be tested in a larger series of patients with warm AIHA and, if the results will be confirmed, it will represent a cheaper and safer treatment than rituximab at standard doses." @default.
• W2525156743 created "2016-10-07" @default.
• W2525156743 creator A5016565948 @default.
• W2525156743 creator A5030528628 @default.
• W2525156743 creator A5036597360 @default.
• W2525156743 creator A5037637576 @default.
• W2525156743 creator A5038654360 @default.
• W2525156743 creator A5039006383 @default.
• W2525156743 creator A5072050682 @default.
• W2525156743 creator A5079569047 @default.
• W2525156743 date "2008-11-16" @default.
• W2525156743 modified "2023-10-16" @default.
• W2525156743 title "Complete Haematological Response after Low Dose Rituximab in a Patient with Refractory Warm-Type Autoimmune Haemolytic Anaemia" @default.
• W2525156743 doi "https://doi.org/10.1182/blood.v112.11.5376.5376" @default.
• W2525156743 hasPublicationYear "2008" @default.
• W2525156743 type Work @default.
• W2525156743 sameAs 2525156743 @default.
• W2525156743 citedByCount "0" @default.
• W2525156743 crossrefType "journal-article" @default.
• W2525156743 hasAuthorship W2525156743A5016565948 @default.
• W2525156743 hasAuthorship W2525156743A5030528628 @default.
• W2525156743 hasAuthorship W2525156743A5036597360 @default.
• W2525156743 hasAuthorship W2525156743A5037637576 @default.
• W2525156743 hasAuthorship W2525156743A5038654360 @default.
• W2525156743 hasAuthorship W2525156743A5039006383 @default.
• W2525156743 hasAuthorship W2525156743A5072050682 @default.
• W2525156743 hasAuthorship W2525156743A5079569047 @default.
• W2525156743 hasConcept C126322002 @default.
• W2525156743 hasConcept C159654299 @default.
• W2525156743 hasConcept C163764329 @default.
• W2525156743 hasConcept C203014093 @default.
• W2525156743 hasConcept C2776309230 @default.
• W2525156743 hasConcept C2777063308 @default.
• W2525156743 hasConcept C2777385706 @default.
• W2525156743 hasConcept C2780580376 @default.
• W2525156743 hasConcept C2780653079 @default.
• W2525156743 hasConcept C2780931953 @default.
• W2525156743 hasConcept C29730261 @default.
• W2525156743 hasConcept C71924100 @default.
• W2525156743 hasConcept C90924648 @default.
• W2525156743 hasConceptScore W2525156743C126322002 @default.
• W2525156743 hasConceptScore W2525156743C159654299 @default.
• W2525156743 hasConceptScore W2525156743C163764329 @default.
• W2525156743 hasConceptScore W2525156743C203014093 @default.
• W2525156743 hasConceptScore W2525156743C2776309230 @default.
• W2525156743 hasConceptScore W2525156743C2777063308 @default.
• W2525156743 hasConceptScore W2525156743C2777385706 @default.
• W2525156743 hasConceptScore W2525156743C2780580376 @default.
• W2525156743 hasConceptScore W2525156743C2780653079 @default.
• W2525156743 hasConceptScore W2525156743C2780931953 @default.
• W2525156743 hasConceptScore W2525156743C29730261 @default.
• W2525156743 hasConceptScore W2525156743C71924100 @default.
• W2525156743 hasConceptScore W2525156743C90924648 @default.
• W2525156743 hasLocation W25251567431 @default.
• W2525156743 hasOpenAccess W2525156743 @default.
• W2525156743 hasPrimaryLocation W25251567431 @default.
• W2525156743 hasRelatedWork W1576996709 @default.
• W2525156743 hasRelatedWork W1993891977 @default.
• W2525156743 hasRelatedWork W2058605959 @default.
• W2525156743 hasRelatedWork W2247248364 @default.
• W2525156743 hasRelatedWork W2335258540 @default.
• W2525156743 hasRelatedWork W2354723882 @default.
• W2525156743 hasRelatedWork W2419609584 @default.
• W2525156743 hasRelatedWork W2506358731 @default.
• W2525156743 hasRelatedWork W2530199867 @default.
• W2525156743 hasRelatedWork W2530807301 @default.
• W2525156743 hasRelatedWork W2557914578 @default.
• W2525156743 hasRelatedWork W2571413983 @default.
• W2525156743 hasRelatedWork W2581921320 @default.
• W2525156743 hasRelatedWork W2583629598 @default.
• W2525156743 hasRelatedWork W2598510972 @default.
• W2525156743 hasRelatedWork W2979578945 @default.
• W2525156743 hasRelatedWork W2980522573 @default.
• W2525156743 hasRelatedWork W3031569523 @default.
• W2525156743 hasRelatedWork W3049743697 @default.
• W2525156743 hasRelatedWork W3189955770 @default.
• W2525156743 isParatext "false" @default.
• W2525156743 isRetracted "false" @default.
• W2525156743 magId "2525156743" @default.
• W2525156743 workType "article" @default.